ReShape Lifesciences Inc. – NASDAQ:RSLS
ReShape Lifesciences stock price today
ReShape Lifesciences stock price monthly change
ReShape Lifesciences stock price quarterly change
ReShape Lifesciences stock price yearly change
ReShape Lifesciences key metrics
Market Cap | 3.12M |
Enterprise value | N/A |
P/E | -0.02 |
EV/Sales | -0.39 |
EV/EBITDA | 0.07 |
Price/Sales | 0.12 |
Price/Book | 0.06 |
PEG ratio | N/A |
EPS | -2.26 |
Revenue | 8.33M |
EBITDA | -11.66M |
Income | -10.91M |
Revenue Q/Q | -14.99% |
Revenue Y/Y | -24.82% |
Profit margin | -577.18% |
Oper. margin | -578.95% |
Gross margin | 61.91% |
EBIT margin | -578.95% |
EBITDA margin | -139.96% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeReShape Lifesciences stock price history
ReShape Lifesciences stock forecast
ReShape Lifesciences financial statements
| Jun 2023 | 2.25M | -3.49M | -154.97% |
|---|---|---|---|
| Sep 2023 | 2.15M | -3.53M | -163.99% |
| Dec 2023 | 1.98M | -1.69M | -85.67% |
| Mar 2024 | 1.94M | -2.19M | -112.81% |
| 2025 | 11.99M | -5.76M | -48.04% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 11852000 | 5.11M | 43.15% |
|---|---|---|---|
| Sep 2023 | 7827000 | 4.74M | 60.61% |
| Dec 2023 | 10727000 | 4.06M | 37.89% |
| Mar 2024 | 8231000 | 3.69M | 44.92% |
| Jun 2023 | -6.66M | -3K | 2.25M |
|---|---|---|---|
| Sep 2023 | -2.78M | 0 | -338K |
| Dec 2023 | -2.45M | 3.20M | 5.46M |
| Mar 2024 | -2.07M | 0 | 0 |
ReShape Lifesciences alternative data
| Aug 2023 | 40 |
|---|---|
| Sep 2023 | 40 |
| Oct 2023 | 40 |
| Nov 2023 | 40 |
| Dec 2023 | 40 |
| Jan 2024 | 40 |
| Feb 2024 | 40 |
| Mar 2024 | 40 |
| Apr 2024 | 40 |
| May 2024 | 29 |
| Jun 2024 | 29 |
| Jul 2024 | 29 |
ReShape Lifesciences other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 0 | 373149 |
| Dec 2022 | 0 | 7357 |
| Jan 2023 | 0 | 158 |
| Feb 2023 | 0 | 260 |
| Mar 2023 | 0 | 109 |
| Apr 2023 | 0 | 96 |
| May 2023 | 0 | 98 |
| Jun 2023 | 17702 | 0 |
| Jul 2023 | 0 | 106 |
| Aug 2023 | 0 | 147 |
| Sep 2023 | 0 | 118 |
| Oct 2023 | 0 | 170 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 131 | $0.27 | $35 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 39 | $0.93 | $36 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 118 | $0.89 | $105 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 39 | $1.42 | $55 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 108 | $1.43 | $154 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 106 | $1.47 | $156 | ||
Purchase | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 17,702 | $1.52 | $26,907 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 98 | $2.41 | $236 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 96 | $2.36 | $227 | ||
Sale | STANKOVICH THOMAS officer: Chief Fi.. | Common Stock, $0.001 par value per share | 109 | $2.6 | $283 |
| Patent |
|---|
Application Filling date: 10 Jan 2022 Issue date: 1 Sep 2022 |
Application Filling date: 21 Jan 2022 Issue date: 14 Jul 2022 |
Application Filling date: 17 Apr 2020 Issue date: 23 Jun 2022 |
Application Filling date: 23 Mar 2021 Issue date: 10 Feb 2022 |
Application Filling date: 4 Oct 2018 Issue date: 28 Oct 2021 |
Application Filling date: 14 Jun 2021 Issue date: 30 Sep 2021 |
Grant Filling date: 27 Jun 2018 Issue date: 15 Jun 2021 |
Application Filling date: 27 Jul 2020 Issue date: 18 Feb 2021 |
Grant Filling date: 21 May 2018 Issue date: 28 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 17 May 2024 | Q1 2024 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
-
What's the price of ReShape Lifesciences stock today?
One share of ReShape Lifesciences stock can currently be purchased for approximately $3.24.
-
When is ReShape Lifesciences's next earnings date?
Unfortunately, ReShape Lifesciences's (RSLS) next earnings date is currently unknown.
-
Does ReShape Lifesciences pay dividends?
No, ReShape Lifesciences does not pay dividends.
-
How much money does ReShape Lifesciences make?
ReShape Lifesciences has a market capitalization of 3.12M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 22.79% to 8.68M US dollars.
-
What is ReShape Lifesciences's stock symbol?
ReShape Lifesciences Inc. is traded on the NASDAQ under the ticker symbol "RSLS".
-
What is ReShape Lifesciences's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of ReShape Lifesciences?
Shares of ReShape Lifesciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ReShape Lifesciences's key executives?
ReShape Lifesciences's management team includes the following people:
- Mr. Barton P. Bandy Pres, Chief Executive Officer & Director(age: 62, pay: $377,000)
- Mr. Thomas Stankovich Senior Vice President of Fin. & Chief Financial Officer(age: 64, pay: $290,000)
-
How many employees does ReShape Lifesciences have?
As Jul 2024, ReShape Lifesciences employs 29 workers, which is 28% less then previous quarter.
-
When ReShape Lifesciences went public?
ReShape Lifesciences Inc. is publicly traded company for more then 8 years since IPO on 6 Oct 2016.
-
What is ReShape Lifesciences's official website?
The official website for ReShape Lifesciences is reshapelifesciences.com.
-
Where are ReShape Lifesciences's headquarters?
ReShape Lifesciences is headquartered at 1001 Calle Amanecer, San Clemente, CA.
-
How can i contact ReShape Lifesciences?
ReShape Lifesciences's mailing address is 1001 Calle Amanecer, San Clemente, CA and company can be reached via phone at +94 94296680.
ReShape Lifesciences company profile:
ReShape Lifesciences Inc.
reshapelifesciences.comNASDAQ
29
Medical - Devices
Healthcare
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
San Clemente, CA 92673
CIK: 0001427570
ISIN: US76090R2004
CUSIP: 761123603
